• 1
    Iwamoto FM,DeAngelis LM. An update on primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2006; 20: 12671285.
  • 2
    DeAngelis LM,Seiferheld W,Schold SC,Fisher B,Schultz CJ, Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002; 20: 46434648.
  • 3
    Abrey LE,Yahalom J,DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000; 18: 31443150.
  • 4
    Gavrilovic IT,Hormigo A,Yahalom J,DeAngelis LM,Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006; 24: 45704574.
  • 5
    Jahnke K,Thiel E,Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006; 80: 159165.
  • 6
    Reni M,Ferreri AJ,Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer. 1999; 79: 530534.
  • 7
    Coiffier B,Lepage E,Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 8
    Pfreundschuh M,Trumper L,Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379391.
  • 9
    Rubenstein JL,Combs D,Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003; 101: 466468.
  • 10
    Witzig TE,White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 37933803.
  • 11
    Witzig TE,Gordon LI,Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 24532463.
  • 12
    Witzig TE,Flinn IW,Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. JClin Oncol. 2002; 20: 32623269.
  • 13
    Lindskoug BA. The Reference Man in diagnostic radiology dosimetry. Br J Radiol. 1992; 65: 431437.
  • 14
    Kolbert KS,Sgouros G,Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997; 38: 301308.
  • 15
    Abrey LE,Batchelor TT,Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23: 50345043.
  • 16
    Wiseman GA,White CA,Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001; 39: 181194.
  • 17
    Gokhale AS,Mayadev J,Pohlman B,Macklis RM. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2005; 63: 194201.
  • 18
    Berinstein NL,Grillo-Lopez AJ,White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998; 9: 9951001.
  • 19
    Conti PS,White C,Pieslor P,Molina A,Aussie J,Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005; 46: 18121818.
  • 20
    Wiseman GA,Leigh BR,Erwin WD, et al. Radiation dosimetry results from a phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003; 18: 165178.
  • 21
    Witzig TE,White CA,Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 12631270.
  • 22
    Wiseman GA,Kornmehl E,Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003; 44: 465474.
  • 23
    Nguyen PL,Chakravarti A,Finkelstein DM,Hochberg FH,Batchelor TT,Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005; 23: 15071513.
  • 24
    Plotkin SR,Betensky RA,Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004; 10: 56435646.
  • 25
    Wong ET,Tishler R,Barron L,Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004; 101: 139145.
  • 26
    Enting RH,Demopoulos A,DeAngelis LM,Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004; 63: 901903.
  • 27
    Pels H,Schulz H,Schlegel U,Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie. 2003; 26: 351354.
  • 28
    DeMonaco NA,Wu M,Osborn J, et al. Phase II trial of abbreviated CHOP-rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood. 2005; 106. Abstract 2449.